Combination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism
Year: 2026
Type: article
Abstract: . Furthermore, combining these two metabolic inhibitors could induce the production of ROS, reduce the generation of ATP, impair mitochondrial morphology and function, and ultimately activate apoptosis in tumor cells through metabolic regulation, facilitating antitumor treatment. The findings underscore the necessity and effectiveness of targeting tumor energy metabolism for lung cancer therapy, providing reliable evidence that metabolic therapies can effectively participate in cancer treatment.
Source: Oncology Reports
DOI: 10.3892/or.2026.9184
Authors: Xinhe Bai, Yongfeng Yang, Yuling Luo, Pei Jing, Xia Hong, Yaqin Zou, Yan Dai, Xuping Yang, Meiling Zhou, Han Xiao, Yilan Huang, Shiwei Guo, Qingze Fan
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7203822023